105 related articles for article (PubMed ID: 23256719)
1. Antioxidants and mucolytics in COPD management: when (if ever) and in whom?
Hillas G; Nikolakopoulou S; Hussain S; Vassilakopoulos T
Curr Drug Targets; 2013 Feb; 14(2):225-34. PubMed ID: 23256719
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress-based therapeutics in COPD.
Barnes PJ
Redox Biol; 2020 Jun; 33():101544. PubMed ID: 32336666
[TBL] [Abstract][Full Text] [Related]
3. COPD: balancing oxidants and antioxidants.
Fischer BM; Voynow JA; Ghio AJ
Int J Chron Obstruct Pulmon Dis; 2015; 10():261-76. PubMed ID: 25673984
[TBL] [Abstract][Full Text] [Related]
4. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.
Hooper C; Calvert J
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):659-69. PubMed ID: 19281081
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol for patients with chronic obstructive pulmonary disease: hype or hope?
Beijers RJHCG; Gosker HR; Schols AMWJ
Curr Opin Clin Nutr Metab Care; 2018 Mar; 21(2):138-144. PubMed ID: 29200030
[TBL] [Abstract][Full Text] [Related]
6. Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review.
Xu Y; Liu H; Song L
J Nanobiotechnology; 2020 Oct; 18(1):145. PubMed ID: 33076918
[TBL] [Abstract][Full Text] [Related]
7. N-acetylcysteine in COPD: why, how, and when?
Sanguinetti CM
Multidiscip Respir Med; 2015; 11():8. PubMed ID: 26855777
[TBL] [Abstract][Full Text] [Related]
8. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
Tse HN; Raiteri L; Wong KY; Yee KS; Ng LY; Wai KY; Loo CK; Chan MH
Chest; 2013 Jul; 144(1):106-118. PubMed ID: 23348146
[TBL] [Abstract][Full Text] [Related]
9. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
[TBL] [Abstract][Full Text] [Related]
10. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
[TBL] [Abstract][Full Text] [Related]
11. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease.
Chalumeau M; Duijvestijn YC
Cochrane Database Syst Rev; 2013 May; (5):CD003124. PubMed ID: 23728642
[TBL] [Abstract][Full Text] [Related]
12. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
13. N-acetylcysteine in COPD may be beneficial, but for whom?
Cazzola M; Matera MG
Lancet Respir Med; 2014 Mar; 2(3):166-7. PubMed ID: 24621673
[No Abstract] [Full Text] [Related]
14. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
15. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
16. Redox signaling at the crossroads of human health and disease.
Zuo J; Zhang Z; Luo M; Zhou L; Nice EC; Zhang W; Wang C; Huang C
MedComm (2020); 2022 Jun; 3(2):e127. PubMed ID: 35386842
[TBL] [Abstract][Full Text] [Related]
17. Oscillococcinum
Aouina H; Bamri A; Vesin A; Danno K; Aubry E; Faure C; Boujedaini N
Drugs Context; 2021; 10():. PubMed ID: 34349821
[TBL] [Abstract][Full Text] [Related]
18. Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive?
Scaglione F; Petrini O
Clin Med Insights Ear Nose Throat; 2019; 12():1179550618821930. PubMed ID: 30670922
[TBL] [Abstract][Full Text] [Related]
19. Expression of diaphragmatic myostatin and correlation with apoptosis in rats with chronic obstructive pulmonary disease.
Zhou X; Yi D; Wu Y; Pei X; Yu H; Chen Y; Jiang Y; Li W
Exp Ther Med; 2018 Mar; 15(3):2295-2300. PubMed ID: 29456636
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic potential of CFTR modulators for COPD and other airway diseases.
Solomon GM; Fu L; Rowe SM; Collawn JF
Curr Opin Pharmacol; 2017 Jun; 34():132-139. PubMed ID: 29132121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
